

21CEC PX PHARM LTD

**Company Registration Number:
04784475 (England and Wales)**

Unaudited micro entity accounts for the year ended 05 April 2023

Period of accounts

Start date: 06 April 2022

End date: 05 April 2023

21CEC PX PHARM LTD

Contents of the Financial Statements

for the Period Ended 05 April 2023

Company Information - 3

Report of the Directors - 4

Profit and Loss Account - 5

Balance sheet - 6

Footnotes to the Balance Sheet - 8

21CEC PX PHARM LTD

Company Information

for the Period Ended 05 April 2023

Director:	Claire Chan Bleasdale
Registered office:	45 Oaklands Westham Pevensey BN24 5AW
Company Registration Number:	04784475 (England and Wales)

21CEC PX PHARM LTD

Directors' Report Period Ended 05 April 2023

The directors present their report with the financial statements of the company for the period ended 05 April 2023

Principal Activities

We provide high quality pharmaceuticals (APIs) to R&D needs of the Universities/Institutions/Laboratories/Companies.

Additional information

Due to the Coronavirus pandemic, Russia-Ukraine war, and high inflation, our business was still in difficulty.

Directors

The director(s) shown below were appointed to the company during the period

Claire Chan Bleasdale

06 April 2022

This report was approved by the board of directors on 30 August 2023

And Signed On Behalf Of The Board By:

Name: Claire Chan Bleasdale

Status: Director

21CEC PX PHARM LTD

Profit and Loss Account

for the Period Ended 05 April 2023

	<i>2023</i> <i>£</i>	<i>2022</i> <i>£</i>
Turnover	10,750	15,100
Cost of Materials	(5,963)	(8,403)
Other charges	(4,536)	(6,239)
Profit or (Loss) for Period	251	458

21CEC PX PHARM LTD

Balance sheet

As at 05 April 2023

	<i>2023</i> <i>£</i>	<i>2022</i> <i>£</i>
Fixed Assets:	2,114	2,114
Current assets:	20,660	17,050
Net current assets (liabilities):	20,660	17,050
Total assets less current liabilities:	22,774	19,164
Total net assets (liabilities):	22,774	19,164
Capital and reserves:	22,774	19,164

21CEC PX PHARM LTD

Balance sheet continued

For the year ending 5 April 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 30 August 2023

And Signed On Behalf Of The Board By:

Name: Claire Chan Bleasdale

Status: Director

The notes form part of these financial statements

21CEC PX PHARM LTD

Footnotes to the Financial Statements

for the Period Ended 05 April 2023

1. Employee Information

Average number of employees: 2

21CEC PX PHARM LTD

Footnotes to the Financial Statements

for the Period Ended 05 April 2023

2. Off balance sheet disclosure

No

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.